The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing vaccine recommendations and assessing whether people receive too ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and 59 ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.